PREVIOUS ISSUE NEXT ISSUE
January 2017 UrologyTimesJanuary2017.png
Anticoagulant use in URS patients ups bleeding riskPatients undergoing ureteroscopy while remaining on anticoagulant therapy may be at increased risk for bleeding complications, including significant bleeding events and unplanned returns to the operating room, according to a retrospective study
Stone retrieval device shows high versatility, efficacyResults from bench studies favor a new open-faced stone retrieval device (Dakota, Boston Scientific) for having greater versatility, efficacy, and durability compared with a competing product, and the in vitro performance of the new instrument is consistent with early clinical experience, says Roger L. Sur, MD.
Use new data to inform unique patient group"Increasingly, urologists are faced with patients who cannot safely discontinue anticoagulation or antiplatelet medications, even in the face of an impending surgical procedure. This is a trend that is likely to continue into the foreseeable future," writes Brian R. Matlaga, MD, MPH.
Study: Statin users less likely to develop kidney stonesA large new study provides more evidence that cholesterol drugs may lower kidney stone formation.
Discordance seen with reporting of food oxalate valuesA study evaluating the oxalate content of foods as reported by two reputable sources shows discordance.
Prostatectomy may be prime target for bundled paymentsAs the federal government moves toward more bundled payments, radical prostatectomy may prove to be an early target because of the potential for overall savings.
How Sanofi’s discontinuation of BCG affects patients, cliniciansSanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.
How will the ProtecT study affect your care of PCa patients?
Committee seeks to ban concurrent surgeriesThe practice of performing concurrent and overlapping surgeries in hospitals and ambulatory surgery centers across the nation has come under scrutiny by the Senate Finance Committee, and hospitals and surgeons are on notice that some practices that may have been commonplace in the past need to change.
BCG instillation: Why you can’t get reimbursed for catheters
CMS data: Health care spending continues to riseRobert A. Dowling, MD, summarizes key findings from the recent CMS report “National Health Spending: Faster Growth In 2015 As Coverage Expands and Utilization Increases."
PCa immunotherapy: Response better when given before ADTAdministering sipuleucel-T (Provenge) before rather than after androgen deprivation therapy in men with biochemically recurrent prostate cancer appears to result in a more robust immunologic response, according to a recent study.
Prostate Ca: Immunotherapy consensus statement publishedStatement authors recommend using immunotherapy prior to an androgen receptor-targeted agent in men with metastatic castration-resistant prostate cancer.
Medical expulsive therapy or bust?Whether or not medical expulsive therapy (MET) is a sound recommendation for patients with kidney or ureteral stones is a matter of debate.
Men's health: What you may have missed in 2016Our #LetsTalkMensHealth section offers clinical tips on the care of male patients. In 2016, articles in this section tackled a variety of subjects, including the Affordable Care Act, epigenetics and genetics, and BPH and prostate cancer prevention.
Letters: Hypoactive desire disorder a 'true' conditionIn this month's Letters to the Editor, one reader responds to an article on testosterone therapy in women and another looks to address urology's work force shortage.
Urology, gynecology collaboration addresses rising demandIn this interview, Sarah E. McAchran, MD, discusses the need for urology-gynecology collaboration, the background behind the ABMS recognizing the female pelvic medicine and reconstructive surgery subspecialty, and how barriers to full integration of providers treating pelvic floor disorders can be overcome.
Uro Pipeline: FDA accepts biologics license application for bladder Ca agentOther pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
How to improve health information online for our patients"Those patients (and their caregivers) who take ownership of more aspects of their health care experience, including relevant and personalized information, will have better outcomes," writes Steven A. Kaplan, MD.
Studies reveal drop in PCa treatment, rise in metastatic diseaseFindings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management.
Bone metastases Tx: 12-week dosing interval appears feasibleResults of a 2-year clinical trial support switching to a less frequent administration schedule when using zoledronic acid (Zometa) to prevent skeletal-related events in men with prostate cancer.
PCa: Emotional distress influences treatment decisionResearchers have found that the anxiety men often experience after being diagnosed with prostate cancer could lead to potentially unnecessary treatment options.
Laser-activated PCa therapy promising in phase III studyResearchers evaluate an experimental treatment called vascular-targeted photodynamic therapy in men with localized prostate cancer.
How patient obesity can impact malpractice litigationWith the New Year being associated with resolutions of improved health and fitness and reducing the number on the scale, it seems a particularly appropriate time to share some information about how obesity impacts urologic care and treatment, and the impact of obesity on malpractice litigation.
How I do it: Best urologic surgery articles of 2016In 2016, our "Hands On" section included articles about bulbomembranous urethroplasty, recurrent urinary tract infections, transgender surgery, and more.
Urolithiasis mortality rate high in lower income nationsResults of a study analyzing global trends in mortality attributable to urolithiasis show that the rate declined over a recent 20-year period.
Selling your practice: How to start the process
Major decline in prostate Bx rates follows PSA publications“It is clear that in order to reduce the morbidity of PSA screening and early detection of prostate cancer, more needs to be done,” writes Badar M. Mian, MD.
Top 10 stone disease articles of 2016A comparison of dusting versus basketing, the question of whether shock wave lithotripsy should be retired, and an expert interview on difficult stones were among the most-read Urology Times articles on stone disease in 2016.
PREVIOUS ISSUE NEXT ISSUE